Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological, Establishing a Fully Integrated Ecosystem
Media OutReach Newswire 
Dual-Driven Strategy: “Commercialization + Innovation” to Build a Leading Vaccine Ecosystem
The vaccine industry is an essential pillar of public health with high entry barriers, stringent oversight, and extended development cycles – all factors contributing to its significant growth potential. As a leading domestic vaccine producer, Kanghua Biological’s flagship product – human diploid cell rabies vaccine – stands as China’s first domestically developed premium vaccine with over a decade of safe application, established market presence and nationwide distribution. The Company also maintains a robust global innovation pipeline, having successfully licensed its recombinant hexavalent norovirus vaccine overseas. This strategic acquisition, focused on critical segments of the vaccine value chain, will strengthen its strategic positioning. The M&A Fund is committed to supporting Kanghua Biological in leveraging its core product line while harnessing the combined strengthens of Shanghai and Chengdu to accelerate the formation of a next-generation vaccine industry ecosystem.
Twin-City Collaboration: Combining “R&D + Manufacturing” to Create a New Industrial Framework
This acquisition marks a significant step to drive Shanghai and Chengdu biopharmaceutical cooperation. Post-transaction, Kanghua Biological will capitalize on Shanghai’s advanced R&D resources and access to top-tier scientific talent and global capital to enhances its industrial capabilities, manufacturing capacity, and market penetration. The M&A Fund will consolidate diverse industrial assets to promote Kanghua Biological’s integration with Shanghai’s R&D and clinical networks, creating an end-to-end collaborative system that spans from “clinical R&D to commercialization” and accelerates the development of a full industrial value chain.
Dual-Channel Empowerment: Driving Corporate Value through “M&A + Integration”
“This transaction goes beyond a typical corporate acquisition, it represents a transformative catalyst for industrial upgrading,” commented Li Chen, Co-President of the M&A Fund. “This exemplifies the complementary strengths created by resource-empowered consolidation. With deep biopharmaceutical, financial, R&D, and global network expertise, Shanghai Healthcare M&A Fund will create significant synergies with Kanghua Biological’s technologies, products, manufacturing, and domestic distribution to have an outsized impact on the sector.”
Hashtag: #SIICCapital #ChengduKanghuaBiological #ShanghaiHealthcareM&AFund
The issuer is solely responsible for the content of this announcement.
About Shanghai Healthcare M&A Fund
A core component of Shanghai’s state-owned capital fund network, Shanghai Healthcare M&A Fund is managed by SIIC Capital, a subsidiary of SIIC Group. The M&A Fund targets Shanghai’s biopharmaceutical sector, aligning government policy objectives with industrial needs by fostering collaboration with leading industry companies, strengthening sector clusters, and enabling asset restructuring. Through capital infusion, improving governance, optimizing management, and executing M&A, the M&A Fund backs “anchor” companies to build complementary and reinforcing links in the value chain, driving the ongoing transformation of specialized subsectors.
About Chengdu Kanghua Biological Products Co., Ltd.
Chengdu Kanghua Biological Products Co., Ltd. is a biopharmaceutical company engaged in research, manufacture and commercialization of biological products. Established in 2004, the company operates an in-house testing center and GMP-certified bacterial and viral vaccine production facilities. Its marketed portfolio includes the ACYW135 meningococcal polysaccharide vaccine and a freeze-dried human diploid cell rabies vaccine. Kanghua holds GMP certification from China’s National Medical Products Administration, has participated in numerous scientific research projects and has been granted patents for over 100 technologies.
